Group 1 - Axo Copper Corp. has successfully closed an upsized bought deal offering, selling 57,500,000 units at a price of $0.70 per unit, resulting in gross proceeds of $40,250,000 [1] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at $1.00 for 18 months [1] - The proceeds from the offering will be used to advance the La Huerta Project and San Antonio Project, as well as for working capital and general corporate purposes [1] Group 2 - The offering was led by Desjardins Capital Markets and BMO Capital Markets, with a cash commission of 6.0% on the gross proceeds paid to the underwriters [2] - The company will issue 2,363,516 common shares to Osisko Development Corp. and 1,180,575 common shares to OR Royalties International Ltd. to maintain their respective ownership interests [3] - The offering was conducted in compliance with applicable securities laws in Canada, except Québec, and is subject to final acceptance by the TSX Venture Exchange [4] Group 3 - Axo Copper Corp. is engaged in the exploration and development of the La Huerta property in Jalisco, Mexico, and the San Antonio gold property in Sonora, Mexico [7]

Core Viewpoint - Petrus Resources Ltd. has successfully closed the acquisition of oil-weighted Cardium assets in the Harmattan area of Alberta for approximately $33.4 million, alongside the completion of equity financings and the approval of its 2026 capital budget and guidance [2][3][5]. Acquisition Details - The acquisition involves oil-weighted Cardium light oil assets in the Harmattan area, with total consideration of approximately $33.4 million, subject to customary adjustments [2]. - The acquisition is expected to enhance the company's production profile and increase its exposure to higher-margin liquids [6]. Equity Financing - Petrus closed an upsized bought-deal private placement and a concurrent non-brokered private placement, issuing 11,814,285 common shares at $1.75 per share, generating gross proceeds of approximately $20.7 million [3]. - The net proceeds from the equity offerings were utilized to repay debt incurred for the acquisition [3]. 2026 Capital Budget and Guidance - The Board of Directors approved a capital budget of $50 million to $60 million for 2026, focusing on developmental drilling in the core Ferrier area and the newly acquired Harmattan assets [5]. - The budget is based on price assumptions of USD $65.00 per barrel for oil and CAD $2.50 per GJ for natural gas [5]. Production and Financial Expectations - Petrus anticipates average production of 11,000 to 12,000 barrels of oil equivalent (boe) per day in 2026, with a mix of approximately 40% oil and liquids and 60% natural gas [7][23]. - The company projects funds flow of $60 million to $65 million, equating to approximately $0.40 per share, and plans to maintain a monthly dividend of $0.01 per share [7]. - The company expects to exit 2026 with net debt of approximately $75 million to $80 million, maintaining a net debt to funds flow ratio of 1.2x to 1.3x [7]. Strategic Focus - The capital program aims to sustain production levels, improve capital efficiencies, and generate free funds flow while integrating the newly acquired assets into the company's operations [4][6]. - Petrus has hedged approximately 57% of its forecasted 2026 production at an average price of CAD $86.22 per barrel for oil and CAD $2.88 per GJ for natural gas, with plans for additional hedging [8].

Core Insights - Herantis Pharma has been selected to lead a consortium for a EUR 8.0 million grant from the Horizon Europe 2025 Research and Innovation program to support a Phase 2 proof-of-concept trial of HER-096 in Parkinson's disease [1][2][3] Funding and Study Details - The funding will facilitate a Phase 2, double-blind, placebo-controlled, randomized efficacy and safety study of HER-096 in early-stage Parkinson's disease patients [2] - The study will commence once necessary preparations, including regulatory approvals, are completed [2] Company Background and Product Information - Herantis Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease, with HER-096 as its lead product [7][8] - HER-096 is a first-in-class small peptide designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF) and is administered subcutaneously [7][9] - Previous clinical trials have shown HER-096 to be generally safe and well-tolerated, with promising preclinical results indicating its potential to stop disease progression and improve patient quality of life [11][10] Horizon Europe Initiative - The Horizon Europe initiative aims to accelerate the translation of biotech research into clinical development, focusing on faster access to innovative therapies, increasing clinical trials in the EU, and enhancing the competitiveness of SMEs in the health biotech sector [6]

Core Insights - SKYX Platforms Corp. has announced a collaboration with NVIDIA AI Ecosystem Connect Program, aiming to enhance its smart home projects and technologies [1] - The company has launched its patented SKYFAN and Turbo Heater at major U.S. retailers, including Home Depot, Target, Walmart, and Lowe's, and expects significant growth in these product lines [1] - SKYX has reported a consistent revenue increase for seven consecutive quarters and anticipates further growth and business opportunities in 2026 [1][2] Financial Performance - As of September 30, 2025, the company reported $13 million in cash and equivalents, and has since raised over $33 million, including a $25 million investment at $2.50 per share [2] - The company has extended $13.5 million in notes due until 2030, strengthening its balance sheet for growth initiatives [2] - SKYX expects to deploy over 100,000 products into homes and units by the end of 2026 through retail and professional segments [2] Product Development and Market Expansion - The company is launching an AI-driven software for its e-commerce platform, projected to increase conversion rates and sales by up to 30% [2] - SKYX has secured strategic manufacturing partnerships globally, including in the U.S., Vietnam, Taiwan, China, and Cambodia [3] - The company aims to deploy over 1 million units of its smart home technologies in various upcoming projects, including a $4 billion smart city in Miami and developments in Saudi Arabia and Egypt [1] Safety and Standardization Efforts - SKYX's Safety Code Standardization Team is making progress towards mandatory safety standards for its ceiling outlet technology, supported by industry veterans [7] - The company believes its products can significantly reduce costs for insurance companies by minimizing risks such as fires and electrocutions [7] - SKYX's technologies are positioned to become a standard feature in homes and buildings, with a total addressable market in the U.S. estimated at $500 billion [7]

From American Rebel Holdings, Inc.’s (NASDAQ: AREB) beverage‑industry launch announcement in October 2023 to today, American Rebel Light Beer has executed a scalable rollout strategy—pairing it’s premium, “better‑for‑you” light lager differentiation with leading distribution relationships that power chain placements, high‑volume on‑premise accounts, and repeat consumer demand in a $110B+ U.S. beer market. NASHVILLE, Tenn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“Amer ...

Core Insights - Landsvirkjun demonstrated strong operational performance in 2025 despite challenging conditions, indicating a solid foundation and financial stability [1][2] - The company faced significant operational strain due to equipment disruptions and challenging conditions in the Þjórsá area, yet all commitments were fulfilled [2] - The financial position remains robust, with a proposed dividend payment of USD 165 million and considerations for a special dividend [4][6] Operational Highlights - Hydrological conditions were volatile, with a prolonged drought at the beginning of the year, but improved significantly by year-end [1] - The company is entering an extensive construction period, with progress on the Vaðalda power station and preparatory work for the Hvammsvirkjun hydropower project [3] Financial Performance - Profit from core operations reached approximately USD 287 million, with an equity ratio of 64.5% and net debt at 1.7x EBITDA [6]

Core Viewpoint - TKM Grupp AS reported a decrease in revenue and net profit for the year 2025, with a proposed dividend distribution to shareholders. Financial Performance - The consolidated audited revenue for 2025 was 919.6 million euros, reflecting a decrease of 2.6% from 944.6 million euros in 2024 [2] - The consolidated audited net profit for 2025 was 17.5 million euros, down from 27.5 million euros in 2024 [3] Business Segments Performance - The net profit (loss) by business segments for 2025 was as follows: - Supermarkets: 9.5 million euros - Department stores: -0.5 million euros - Car Trade: 4.3 million euros - Security: 0.0 million euros - Real Estate: 6.3 million euros - IFRS16 related loss: -2.1 million euros [3] Dividend Proposal - The Management Board proposed a dividend of 0.60 euros per share, totaling 24.4 million euros, with an income tax payable on dividends of 6.7 million euros [3] - The list of shareholders entitled to dividends will be fixed on 31 March 2026, with the ex-dividend date set for 30 March 2026, and payment scheduled for 7 April 2026 [3] Company Overview - TKM Grupp AS is one of the largest retail groups in Estonia, comprising various subsidiaries including Selver AS, Kaubamaja AS, and others, with over 750 thousand loyal customers at the end of the reporting year [4]

Core Insights - Sagtec Global Limited is expanding its revenue-generating AI ecosystem as enterprise adoption accelerates across various industries [1] - The company is transitioning to a scalable platform-driven business model focused on recurring SaaS subscriptions and AI workflow automation [2] Revenue Growth and Enterprise Pipeline - Recent commercial momentum includes a US$4.0 million deployment of a Smart AI mobility platform, showcasing Sagtec's ability to convert AI innovations into revenue [3] - The company's platform architecture allows clients to scale usage over time, creating potential for recurring revenue growth [3] AI-Native Operating Layer - Sagtec is developing a modular AI operating layer that integrates AI agents, SaaS applications, and microservices within a unified ecosystem [4] - This approach aims to align Sagtec with emerging enterprise AI infrastructure trends and create opportunities for margin expansion [4] Market Expansion Strategy - Sagtec is expanding beyond Southeast Asia into the United States and other strategic markets, targeting sectors experiencing rapid AI transformation [5] - The company aims to increase contract sizes by combining AI integrations with SaaS subscriptions and enterprise customization services [5] Management Vision - The CEO emphasizes the goal of evolving Sagtec into a scalable AI SaaS revenue platform to capture recurring revenue opportunities [6] - Key offerings include AI-driven SaaS deployments, subscription-based workflow platforms, and long-term enterprise integration contracts [6] Revenue Model and Customer Value - The company focuses on predictable recurring income streams and usage-driven monetization [7] - Higher lifetime customer value is anticipated through cross-platform integrations [7] Target Industries - Sagtec is targeting mobility and digital transport ecosystems, retail and food & beverage automation, and enterprise productivity workflows [8]

Core Insights - Myriad Genetics announced the publication of the analytical validation of the FirstGene Multiple Prenatal Screen, demonstrating exceptional sensitivity and specificity for each test component [1][2] Group 1: Test Validation and Performance - The study assessed nearly 500 samples and found that every component of the FirstGene screen achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity [2] - The FirstGene screen is designed to analyze key aspects of maternal and fetal genomes simultaneously, enhancing accuracy and reproducibility [3] Group 2: Clinical Application and Utility - The FirstGene screen aims to streamline prenatal genetic risk assessment by combining aneuploidy screening, recessive screening, and fetomaternal antigen testing into a single assay [4] - The screen is currently being utilized in the CONNECTOR study, which evaluates its performance in real-world clinical practice and aims to support clinical validity and utility [5] Group 3: Technological Innovation - The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to improve genotype resolution [3] - The publication of these results is considered a significant milestone towards the broad commercialization of the FirstGene screen [3]

Group 1 - ArrowMark Financial Corp. announced the preliminary results of its transferable rights offering, which commenced on January 22, 2026, and expired on February 18, 2026, allowing rights holders to subscribe for up to 2,604,156 shares of common stock at a subscription price of $19.79 per share [1][2] - The gross proceeds from the offering are expected to be approximately $37,000,000, which the Fund intends to invest in accordance with its investment objectives and policies [2] Group 2 - ArrowMark Financial Corp. is a non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol "BANX," with an investment objective to provide shareholders with current income by primarily investing in regulatory capital securities of financial institutions [4]